We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients (ANTHICUS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00543894
First Posted: October 15, 2007
Last Update Posted: August 12, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A prospective, observational, multicenter study (ANTHICUS).

Condition
Infection in ICU

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Secondary Outcome Measures:
  • the frequency of appropriate antibiotic therapy (defined as the use of antibiotic(s) with "in vitro" efficacy against the identified pathogens responsible for the infection)
  • the frequency of "the strategy of de-escalation" according to the culture results

Enrollment: 500
Study Start Date: February 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Criteria

Inclusion Criteria:

  • Patients with hospital-acquired infections and hospitalised in the ICU at one moment of their hospital stay
  • Hospital-acquired infections accounting for eligibility are:

    • nosocomial pneumonia (including ventilator-associated pneumonia)
    • bacteremia
    • intra-abdominal infections
    • urosepsis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543894


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Pr Vogelaers UZ Gents
  More Information

ClinicalTrials.gov Identifier: NCT00543894     History of Changes
Other Study ID Numbers: SRP-HB-MER-2005/1
First Submitted: October 11, 2007
First Posted: October 15, 2007
Last Update Posted: August 12, 2008
Last Verified: June 2007

Keywords provided by AstraZeneca:
Antibiotic, ICU, hospital acquired infection.

Additional relevant MeSH terms:
Infection
Communicable Diseases
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents